PRAX vs. BHVN, MTSR, ACAD, MOR, RXRX, XENE, AMRX, CPRX, HCM, and BHC
Should you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Biohaven (BHVN), Metsera (MTSR), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Recursion Pharmaceuticals (RXRX), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry.
Praxis Precision Medicines vs.
Praxis Precision Medicines (NASDAQ:PRAX) and Biohaven (NYSE:BHVN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, community ranking, risk and analyst recommendations.
67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 16.0% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Biohaven had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 6 mentions for Biohaven and 4 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.07 beat Biohaven's score of 0.81 indicating that Praxis Precision Medicines is being referred to more favorably in the media.
Biohaven received 357 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. However, 74.24% of users gave Praxis Precision Medicines an outperform vote while only 67.33% of users gave Biohaven an outperform vote.
Praxis Precision Medicines presently has a consensus target price of $123.33, suggesting a potential upside of 217.22%. Biohaven has a consensus target price of $62.77, suggesting a potential upside of 132.65%. Given Praxis Precision Medicines' higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Biohaven.
Praxis Precision Medicines has a beta of 2.76, meaning that its share price is 176% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.
Praxis Precision Medicines has higher revenue and earnings than Biohaven. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Biohaven has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -9,409.22%. Praxis Precision Medicines' return on equity of -54.86% beat Biohaven's return on equity.
Summary
Biohaven beats Praxis Precision Medicines on 10 of the 18 factors compared between the two stocks.
Get Praxis Precision Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Praxis Precision Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:PRAX) was last updated on 3/28/2025 by MarketBeat.com Staff
